India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Friday the launch of Dapagliflozin Tablets, 5 mg and 10 mg, in the United States.
Lupin's Abbreviated New Drug Application for Dapagliflozin Tablets was approved by US Food and Drug Administration (FDA) as bioequivalent to Farxiga for the indications in the approved labelling.
Farxiga, a brand of biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN), is indicated for the treatment of type 2 diabetes, chronic kidney disease, and symptomatic chronic heart failure.
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
Lupin's Dapagliflozin Tablets launched in US market
Eli Lilly launches Foundayo weight‑loss pill in the US
Lupin's Dapagliflozin Tablets receive US regulatory approval
Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval
Innovent and Ollin Biosciences report IBI324 study data in wAMD and DME
AROA Biosurgery completes Symphony trial in patients with diabetic foot ulcers
Novo Nordisk's Awiqli once-weekly basal insulin treatment approved by US FDA
Kodiak Sciences reports positive Phase 3 results for Zenkuda in diabetic retinopathy
Maze Therapeutics reports positive Phase 2 data for MZE829 in patients with AMKD
Andel launches new direct-to-employer medication platform for GLP-1s
Dexcom highlights new diabetes outcomes and product roadmap at ATTD 2026
Cedar Health Research opens new embedded research site within Texas Native Health